This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

DISC-PRO

Celtic Pharmaceutical Holdings L.P.

Drug Names(s): DISC-PRO

Description: Xenova is developing a disabled infectious single cycle (DISC) herpes simplex virus type 2 (HSV-2) as a novel prophylactic vaccine for the prevention of oral-facial and genital herpes. In this virus, designated DISC-PRO, the gene encoding glycoprotein H, which is essential for cell infection by HSV-2, is deleted. After inoculation into humans or animals, DISC-PRO undergoes only one round of replication, producing non-infectious progeny. All viral antigens (except gH) will therefore be produced within the cell and should stimulate a broad cell-mediated immune response following vaccination

Deal Structure: In September 2005, Celtic Pharmaceutical completed its takeover of Xenova Group plc.


DISC-PRO News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug